Hypericum extract WS^® 5570 for depression – An overview

Abstract

Objective. WS^® 5570 is a Hypericum (St. John's wort) dry extract that is available as a medicinal product in coated tablets and has a marketing authorisation for the acute treatment of mild to moderate major depression in Germany. Methods. This article summarizes the current state of knowledge regarding the clinical efficacy and safety of WS^® 5570. Results. In randomised, double-blind, controlled clinical trials the antidepressant effect of the drug was superior to that of the placebo and at least comparable to that of paroxetine. The beneficial effect of WS^® 5570 is particularly pronounced with respect to the core symptoms of depression. There is evidence that the drug may also be effective in moderate to severe depression and in prophylactic continuation treatment after recovery from an acute episode. Conclusions. WS^® 5570 has a very favourable safety profile, with adverse event rates on one level with placebo and lower than that of synthetic antidepressants in randomised, controlled clinical trials. It may therefore also be an option for patients who do not tolerate other antidepressant drugs. Patients with polydrug treatment should nevertheless use the drug with caution, due to its potential for interactions.

Key words::

• Hypericum
• St. John's wort
• depression
• overview
• efficacy
• safety

Acknowledgements

None.

Statement of interest

None of the author reports conflicts of interest.

Notes

¹WS^® 5570 is the active substance of Neuroplant^® (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany).